Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Magnesium-sensitive upstream ORF controls PRL phosphatase expression to mediate energy metabolism.

Serge Hardy | Elie Kostantin | Shan Jin Wang | Tzvetena Hristova | Gabriela Galicia-Vázquez | Pavel V Baranov | Jerry Pelletier | Michel L Tremblay
Proceedings of the National Academy of Sciences of the United States of America | 2019

Phosphatases of regenerating liver (PRL-1, PRL-2, and PRL-3, also known as PTP4A1, PTP4A2, and PTP4A3) control magnesium homeostasis through an association with the CNNM magnesium transport regulators. Although high PRL levels have been linked to cancer progression, regulation of their expression is poorly understood. Here we show that modulating intracellular magnesium levels correlates with a rapid change of PRL expression by a mechanism involving its 5'UTR mRNA region. Mutations or CRISPR-Cas9 targeting of the conserved upstream ORF present in the mRNA leader derepress PRL protein synthesis and attenuate the translational response to magnesium levels. Mechanistically, magnesium depletion reduces intracellular ATP but up-regulates PRL protein expression via activation of the AMPK/mTORC2 pathway, which controls cellular energy status. Hence, altered PRL-2 expression leads to metabolic reprogramming of the cells. These findings uncover a magnesium-sensitive mechanism controlling PRL expression, which plays a role in cellular bioenergetics.

Pubmed ID: 30718434

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Wellcome Trust, United Kingdom
  • Agency: Canadian Institutes of Health Research, International
    Id: MOP-142497
  • Agency: Canadian Institutes of Health Research, International
    Id: FDN-159923
  • Agency: Canadian Institutes of Health Research, International
    Id: FDN-14366
  • Agency: Wellcome Trust, United Kingdom
    Id: 210692/Z/18/Z

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.